• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)

by last | Nov 13, 2022 | 2022, Eventi

Philogen will attend the TIDES Europe in Vienna in November 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture entitled “Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast...

Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging

by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific

The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

by Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors.   The...

Philogen publishes a new study on OncoFAP in Clinical Cancer Research

by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific

The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...

Philogen’s management team held a webinar on 29 September 2022 at 16:00 CEST

by last | Sep 28, 2022 | 2022, Past Events

Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...

Philogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.

by Lisa Nadal | Sep 15, 2022 | 2022, Press Releases, Scientific

The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More details
« Older Entries

Recent Posts

  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
  • Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)
  • Philochem will be attending the 10th World ADC Conference in London
  • Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
  • Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch